Carcinoma endometrium: Role of 18-FDG PET/CT for detection of suspected recurrence

Clinical Nuclear Medicine

Volumn 37, Issue 7, 2012, Pages 649-655

  Sharma, Punit ^a   Kumar, Rakesh ^a   Singh, Harmandeep ^a   Jeph, Sunil ^a   Sharma, Daya Nand ^a   Bal, Chandrasekhar ^a   Malhotra, Arun ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

carcinoma endometrium; FDG; PET CT; recurrence

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ABDOMINAL WALL METASTASIS; ADRENAL METASTASIS; ADULT; ARTICLE; BONE METASTASIS; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ENDOMETRIUM CARCINOMA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PANCREAS METASTASIS; PERITONEUM METASTASIS; PREDICTIVE VALUE; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SKIN METASTASIS; SPLEEN METASTASIS;

ADENOCARCINOMA; ADULT; AGED; ENDOMETRIAL NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RECURRENCE;

EID: 84862509871     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e31824d24fa     Document Type: Article

References (34)

1. Morrow CP, Bundy BN, Kurman RJ, et al. Relationship between surgicalpathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: A Gynecologic Oncology Group study. Gynecol Oncol. 1991;40: 55-65.
2. Irvin WP, Rice LW, Berkowitz RS. Advances in the management of endometrial adenocarcinoma. A review. J Reprod Med. 2002;47:173-189.
3. Aalders JG, Abeler V, Kolstad P. Recurrent adenocarcinoma of the endometrium: A clinical and histopathological study of 379 patients. Gynecol Oncol. 1984;17:85-103.
4. Kao MS. Management of recurrent endometrial cancer. Chang Gung Med J. 2004;27:639-645.
5. Pazdur R, Coia LR, Hoskins WJ, et al. Cancer Management: A Multidisciplinary Approach. 5th ed. New York, NY: PRR; 2001.
6. Benedet JL, Bender H, Jones H III, et al. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet. 2000;70: 209-262.
7. Jeyarajah AR, Gallagher CJ, Blake PR, et al. Long-term follow-up of gonadotrophin-releasing hormone analog treatment for recurrent endometrial cancer. Gynecol Oncol. 1996;63:47-52.
8. Moore TD, Phillips PH, Nerenstone SR, et al. Systemic treatment of advanced and recurrent endometrial carcinoma: Current status and future directions. J Clin Oncol. 1991;9:1071-1088.
9. Huang HJ, Lai CH, Tsai CS, et al. Radical resection and intraoperative radiotherapy for a recurrent endometrial cancer after prolonged remission following aggressive salvage therapy: Case report. Chang Gung Med J. 1999;22: 654-659.
10. Connor JP, Andrews JI, Anderson B, et al. Computed tomography in endometrial carcinoma. Obstet Gynecol. 2000;95:692-696.
11. Cherchi PL, Dessole S, Ruiu GA, et al. The value of serum CA 125 and association CA 125/CA 19-9 in endometrial carcinoma. Eur J Gynaecol Oncol. 1999;20:315-317.
12. Manfredi R, Mirk P, Maresca G, et al. Local-regional staging of endometrial carcinoma: Role of MR imaging in surgical planning. Radiology. 2004;231: 372-378.
13. Kinkel K, Ariche M, Tardivon AA, et al. Differentiation between recurrent tumor and benign conditions after treatment of gynecologic pelvic carcinoma: Value of dynamic contrast-enhanced subtraction MR imaging. Radiology. 1997; 204:55-63.
14. Kluetz PG, Meltzer CC, Villemagne VL, et al. Combined PET/CT Imaging in Oncology. Impact on Patient Management. Clin Positron Imaging. 2000;3: 223-230.
15. Yen TC, Ng KK, Ma SY, et al. Value of dual-phase 2-fluoro-2-deoxy- Dglucose positron emission tomography in cervical cancer. J Clin Oncol. 2003; 21:3651-3658.
16. Zimny M, SiggelkowW, SchroderW, et al. 2-[lsqb]Fluorine-18[rsqb]-fluoro- 2-deoxy-D-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer. Gynecol Oncol. 2001;83:310-315.
17. Ryu SY, Kim K, Kim Y, et al. Detection of recurrence by 18F-FDG PET in patients with endometrial cancer showing no evidence of disease. J Korean Med Sci. 2010;25:1029-1033.
18. Kitajima K, Murakami K, Yamasaki E, et al. Performance of integrated FDGPET/contrast-enhanced CT in the diagnosis of recurrent uterine cancer: Comparison with PET and enhanced CT. Eur J Nucl Med Mol Imaging. 2009;36: 362-372.
19. Kitajima K, Murakami K, Yamasaki E, et al. Performance of FDG-PET/CT in the diagnosis of recurrent endometrial cancer. Ann Nucl Med. 2008;22: 103-109.
20. Chung HH, Kang WJ, Kim JW, et al. The clinical impact of [(18)F]FDG PET/CT for the management of recurrent endometrial cancer: Correlation with clinical and histological findings. Eur J Nucl Med Mol Imaging. 2008;35: 1081-1088.
21. Sironi S, Picchio M, Landoni C, et al. Post-therapy surveillance of patients with uterine cancers: Value of integrated FDG PET/CT in the detection of recurrence. Eur J Nucl Med Mol Imaging. 2007;34:472-479.
22. Rebollo-Aguirre AC, Ramos-Font C, Gallego Peinado M, et al. Positron emission tomography with fluordesoxyglucose-F18 in follow-up of endometrial cancer. Rev Esp Med Nucl. 2006;25:359-366.
23. Saga T, Higashi T, Ishimori T, et al. Clinical value of FDG-PET in the follow up of post-operative patients with endometrial cancer. Ann Nucl Med. 2003;17: 197-203.
24. Belhocine T, De Barsy C, Hustinx R, et al. Usefulness of (18)F-FDG PET in the post-therapy surveillance of endometrial carcinoma. Eur J Nucl Med Mol Imaging. 2002;29:1132-1139.
25. Kitajima K, Suzuki K, Nakamoto Y, et al. Low-dose non-enhanced CT versus full-dose contrast-enhanced CT in integrated PET/CT studies for the diagnosis of uterine cancer recurrence. Eur J Nucl Med Mol Imaging. 2010;37: 1490-1498.
26. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
27. Creutzberg CL, Van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: Multicentre randomised trial. Portec Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet. 2000;355:1404-1411.
28. Disaia PJ, Creasman WT. Clinical Gynecologic Oncology. 6th ed. St. Louis, MO: Mosby; 2001.
29. Barakat RR, Greven K, Markman M, et al. Cancer management. A multidisciplinary approach. In: Endometrial Cancer. 5th ed. New York, NY: PRR Inc; 2001.
30. Warburg O. The Metabolism of Tumors. London, United Kingdom: Arnold Constable; 1930:75-327.
31. Lerman H, Metser U, Grisaru D, et al. Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre- and postmenopausal patients: Assessment by PET/CT. J Nucl Med. 2004;45:266-271.
32. Park JY, Kim EN, Kim DY, et al. Clinical impact of positron emission tomography or positron emission tomography/computed tomography in the posttherapy surveillance of endometrial carcinoma: Evaluation of 88 patients. Int J Gynecol Cancer. 2008;18:1332-1338.
33. Fischer BM, OlsenMW, Ley CD, et al. How few cancer cells can be detected by positron emission tomography? A frequent question addressed by an in vitro study. Eur J Nucl Med Mol Imaging. 2006;33:697-702.
34. Nakamoto Y, Chin BB, Kraitchman DL, et al. Effects of nonionic intravenous contrast agents at PET/CT imaging: Phantom and canine studies. Radiology. 2003;227:817-824.